The Excellos Difference
Up to now, variabilities in results have limited clinical benefits and use of cell and gene therapy for the treatment of cancer. This variability is the result of three main factors: tumor/host biology, inherent tumor resistance mechanisms, and variability in the cell therapy product itself (Figure 1).
Polyfunctional Strength Index (PSI). PSI has been shown to correlate with clinical response characterizes the effector killing potential of T cell subsets isolated from healthy donors. Data demonstrates substantial variability in healthy donors’ Effector Function Indices (EFI) and a trend for younger donors to have higher EFI. Also shown is that different donor T cell populations have different Effector Function Indices.
Excellos 360 employs Excellos’s deep cell characterization approach to address these by going deeper than typical cell and donor screening to create a comprehensive immune cell profile for each donor, as well as an assessment of the metabolic and effector potential of their cells that looks beyond surface markers.
Using this approach, Excellos 360 is working to improve the potency of cell-based treatments to reduce clinical response variability, in order to:
- Improve clinical outcomes,
- Lower safety liability by making therapies effective in lower dosages
- Lower the cost of goods associated with cell and gene therapy manufacture.
Achieving these goals will allow therapeutic developers to accelerate the development and production of immunotherapy treatments, increasing their use and accessibility.